Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone

An anti-parasite and thymol technology, which is applied in the direction of drug combination, medical preparations containing active ingredients, active ingredients of hydroxyl compounds, etc., can solve the problems of life quality impact, difficult treatment of patients, shortened life expectancy, etc., and achieve reduction cost effect

Inactive Publication Date: 2008-05-07
ADVANCED SCIENTIFICS INC
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] For example, immunosuppressed patients in particular will become increasingly difficult to treat and their life expectancy will be correspondingly shortened
In addition, their quality of life is also greatly affected due to the high doses of therapeutic drugs given

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0064] Example 1: Treatment of chicken balls with carvacrol or thymol synergistic salinomycin Bug disease

[0065] These in vivo experiments were designed to measure weight gain, wasting index, daily cyst shedding and fecal appearance in treated birds.

[0066] The subjects of this experiment were 200 22-day-old subclinical coccidiosis chickens (average weight 620 g), sampled from a flock of 10,000 broilers. Subclinical coccidiosis was diagnosed on day 20. The mean cyst shedding in this experimental animal was 50,000 cysts / g (OPG).

[0067] Microscopic examination revealed the presence of two Eimeria genera: Eimeria acervulina and Eimeria tenella.

[0068] The antiparasitic used was salinomycin, one of the most widely prescribed antiparasitics for this type of infection. The two antiparasitic pharmaceutical compositions according to the present invention are prepared by mixing different concentrations of salinomycin with sub-inhibitory concentrations of carvacrol or thym...

example 2

[0087] Example 2: Intrinsic antimalarial effects of eugenol and carvacrol and synergistic effect of artesunate

[0088] In vitro test: IC 50 (Concentration required for 50% inhibition of parasite growth) Determination

[0089] The experiments were performed in 4 clones (designated 3d7, HB3, Dd2 and 7G8) of the malaria pathogen Plasmodium falciparum, a parasitic disease also known as malaria. These clones are laboratory reference models commonly used to screen drugs for antimalarial activity.

[0090] Plasmodium falciparum grows on human red blood cells. The assay is performed in 96-well plates in which infected erythrocytes (synchronized with sorbitol) are incubated at 37°C under gas-controlled (5% CO 2 , 1% O 2 ,,94%N 2 ) received different treatments for 72 hours in an incubator. Pathogen growth is measured by quantifying fluorescent DNA in the presence of SybrGreen.

[0091] One of the most effective antiparasitic drugs, artesunate, was tested. The antiparasitic p...

example 3

[0103] Example 3: Intrinsic antimalarial effect of eugenol and synergistic effect of chloroquine.

[0104] In vitro test: IC 50 Determination of (concentration required for 50% inhibition of parasite growth)

[0105] This experiment was carried out in the same Plasmodium falciparum clones (3d7, HB3, Dd2 and 7G8) as in Example 2, the first two clones (3d7 and HB3) were sensitive to chloroquine and the other two (Dd2 and 7G8) were sensitive to chloroquine drug resistance.

[0106] One of the most widely used antiparasitic drugs, chloroquine, was tested. The antiparasitic pharmaceutical composition according to the present invention is prepared by mixing different concentrations of chloroquine with sub-inhibitory concentrations of 0.2mM eugenol, which is higher than the IC of eugenol alone. 50 2 to 6-fold lower (depending on clone). The pharmaceutical composition is named as chloroquine-eugenol, and the letter P represents the synergistic effect of eugenol.

[0107] In eac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition. The pharmaceutical composition comprises: at least one first therapeutically-active substance which is selected from carveol, thymol, eugenol, borneol, carvacrol and the isomers, derivatives and mixtures thereof; and at least one second therapeutically-active substance which is selected from an antiviral agent, an antitumour agent and an antiparasitic agent.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising two therapeutically active substances, one of which exerts a synergistic effect on the other; and to the use of this composition. Background technique [0002] It is known that the effect of therapeutic drugs depends on the dose used, and in the case of partial drug resistance, it is necessary to increase the dose of therapeutic drugs in order to achieve the desired effect. Dosage increases lead to problems of adverse reactions and acute or chronic toxicity, which can greatly complicate the condition of the treated patient. [0003] This partial resistance may become complete resistance. In this case, increasing the dose no longer had any beneficial therapeutic effect; only toxic effects were observed. Treatment in this case consists in changing the medication. [0004] This chain of events is itself repeatable and leads to the most severe scenario: complete resistance to multi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P31/12A61P33/00A61P33/10A61P35/00A61K45/06A61K31/045A61K31/05
CPCA61K31/05A61K45/06A61K31/045A61P31/12A61P33/00A61P33/10A61P35/00Y02A50/30A61K2300/00
Inventor 阿德南·雷梅尔
Owner ADVANCED SCIENTIFICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com